Another strong year for Shire with revenues exceeding $4 billion for the first
time and Non GAAP EPS up 26% to $5.34.
Good 2012 earnings growth expected.
February 9, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces results for the year to December 31, 2011.
Financial Highlights Full Year 2011(1)
Product sales $3,950 million +26%
Total revenues $4,263 million +23%
Non GAAP operating income $1,357 million +27%
US GAAP operating income $1,109 million +40%
Non GAAP diluted earnings per ADS $5.34 +26%
US GAAP diluted earnings per ADS $4.53 +43%
Non GAAP cash generation $1,391 million +3%
Non GAAP free cash flow $879 million +11%
US GAAP net cash provided by operating activities $1,074 million +12%
